Tenders

Open House Discount Contracts 2023-05

Extension of a Non-Exclusive Framework Contract "Direct Personnel Placement

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Formoterol/Aclidinium Bromide (Atc Code According to Who: R03al05)

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Formoterol/aclidinium Bromide (atc Code According to Who: R03al05)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Sultamicillin (Atc Code: J01cr04).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Fulvestrant (Atc Code: L02ba03).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Interferon Beta-1B (Atc:L03ab08).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Combination of Metoprolol and Hydrochlorothiazide (C07bb22).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Combination of Formoterol and Aclidinium Bromide (Atc Code: R03al05).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Valproic Acid (Atc Code: N03ag01).